Disclosures: Conflict of interest
Disclosures: N. Cross: Scientific Advisory board: Novartis P. Fenaux:: No conflicts of interest G. Garcia-Manero: No conflicts of interest R. Itzykson: No conflicts of interest J-J. Kiladjian: Scientific Advisory boards: Novartis, Sanofi, Shire, AOP Orphan; Research grants: Celgene, Novartis. R. Komrokji: Consultancy: Celgene and Incyte; Research support: Celgene and Incyte A. List: Consultancy: CTI; Scientific Advisory Board: Celgene, Teralogics J. Maciejewski: Speakers' bureau: Alexion, Celgene, Eisai R. Mesa: Research support from Incyte, Lilly, NS Pharma, Sanofi, Gilead, CTI, Genentech L. Malcovati: No conflicts of interest G. Mufti: No conflicts of interest T. Mughal: Consultancy: Incyte and Novartis A. Orazi: Scientific Advisory boards: Incyte and Novartis E. Padron: Speakers' bureau: Incyte and Novartis; Research Support: KaloBios Pharmaceuticals M. Savona: Consultancy: Karyopharm; Scientific Advisory Board: Celgene, Gilead, Incyte, Karyopharm, Novartis E. Solary: No conflicts of interest R. Tibes: Research support from Astex, Abbott, Celgene, Novartis, Merck R. Tiu: Speakers' bureau: Incyte, Cephalon and Bristol-Myers Squibb

Contributions: Authorship contributions TM, AL, NC, ES, JM and MS designed the outline strategy. TM wrote the preliminary and the final version of the paper. All authors formed the working group and participated in writing significant sections of the paper.